Analysis of the assortment of drugs used in Parkinson's disease in the pharmaceutical market of the republic of Uzbekistan

Аннотация

In the Republic of Uzbekistan, special attention is paid to modern approaches to the treatment of Parkinson's disease and the prospects of new drugs. Given the advances in Parkinson's disease research and the emergence of new drugs, it is important to conduct an analysis of the range of drugs used in Parkinson's disease. Assortment analysis of the pharmaceutical market is aimed at studying the offer of drugs used in the treatment of Parkinson's disease. This article analyzes the assortment of drugs used in the treatment of Parkinson's disease registered in the years 2013-2023 of the State Register of drugs, medical products and medical equipment authorized for use in medical practice in the Republic of Uzbekistan [1,2,3]. The results of the assortment analysis are presented in the context of patient needs and quality requirements, which can be useful for manufacturers, distributors and researchers in the pharmaceutical industry. Keywords: Parkinson's, range analysis. pharmaceutical market, marketing analysis. can be alleviated with various therapies and Introduction: Worldwide, Parkinson’s disease occurs in medications. The most common symptoms of 120-150 people per 100,000 population, meaning 1–3 Parkinson's disease include tremors, pain, involuntary out of every 1,000 individuals (0.1–0.3%) are affected. muscle contractions, and slurred speech. The disease It is the second most common neurodegenerative usually occurs in the elderly, but it can also occur in disease after Alzheimer’s disease. According to the young people. It affects men more than women. WHO, more than 6 million people worldwide suffer from Parkinson's disease, and their number is expected In recent years, foreign drugs for the treatment of to increase to 8.7-9.3 million by 2030. The prevalence Parkinson's disease are increasingly used in the of Parkinson's disease in the world is 120 to 180 per pharmaceutical market. Deep research on this topic has 100,000 population and is 1% in people over 60 years not yet been conducted in Uzbekistan. Despite this, the old and 4% in people over 80 years old. In Russia, the production of such drugs in our country increases every total incidence is 1.88-16.3 per 100,000 population per year and fills the markets of Uzbekistan. year. In recent years, the number of people diagnosed Purpose of work with Parkinson’s disease in Uzbekistan has been The purpose of our work is to analyze the increasing. Parkinson's disease symptoms worsen over pharmaceutical market of the Republic of Uzbekistan time. There is no cure for the disease, but its symptoms International Journal of Medical Sciences And Clinical Research 16 https://theusajournals.com/index.php/ijmscr International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265) and to analyze the range of drugs used in the treatment depth (3), and the assortment structure (4), where: of Parkinson's disease. Determining the scarcity or IO=m/M (1), m – the number of new product names, M limitation of medications needed to treat Parkinson's – the total number of product names approved for use disease, their imported or domestically produced in the country. Kw=Wfact/Wbase (2), Wfact – the quantities. The breadth of the range of medications number of groups or subgroups of products available in necessary for patients was determined. In addition, a the organization or produced by the industry, Wbase – comparative analysis of the range of drugs used in the number of groups or subgroups of products Parkinson's disease in the domestic pharmaceutical approved for use in the country and listed in the State market during the period 2013-2023 y. This study aims Register of Medicines and Medical Devices. to improve the quality of life of patients with Kd=Dfact/Dbase (3), Dfact – the number of names of Parkinson's disease, systematically develop the medicinal products within a single active pharmaceutical market, and increase the volume of pharmaceutical ingredient (API) or domestic drug production. pharmacotherapeutic group available in the studied sector, Dbase– the number of names of medicinal Experimental section. products within a single API or pharmacotherapeutic Research materials and methods group approved for use in the country. Share of The main sources of information for this article include: pharmacotherapeutic group (PTG) (%) = (A_ptg/A_o - State Register of medicines, medical supplies and )×100% (4), Aptg– the assortment of the medical equipment approved for use in medical pharmacotherapeutic group (number of product practice in the Republic of Uzbekistan (2013-2023). names), Ao – the total assortment (number of product names)[6]. Content analysis methodology and logical abstract comparison method were chosen as research methods RESULTS [4,5]. In addition, the research employed methods of According to the state registry, the following results statistical data processing: correlation, regression, were released, which will be discussed in more detail ana